TAM
DMAC icon

Tocqueville Asset Management’s DiaMedica Therapeutics DMAC Stock Holding History

Tocqueville Asset Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$71.1K Buy
+10,500
New +$83.2K ﹤0.01% 545

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Tocqueville Asset Management's DMAC Position: Q1 2026 in Review

Tocqueville Asset Management opened a new position in DiaMedica Therapeutics (DMAC) in Q1 2026: 10,500 shares worth $71.1K. The stake represents ﹤0.01% of the portfolio and ranks #545 among its holdings.

98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Tocqueville Asset Management held 10,500 shares of DiaMedica Therapeutics worth $71.1K as of Q1 2026.
  • DiaMedica Therapeutics was a new Tocqueville Asset Management position in Q1 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of Tocqueville Asset Management's portfolio in Q1 2026, its #545 holding.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Tocqueville Asset Management's 13F filing for Q1 2026, filed 12 May 2026.